Welcome to our dedicated page for Integral Ad Science Holding SEC filings (Ticker: IAS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Advertising verification may sound simple, but Integral Ad Science’s business model rests on complex data licensing, recurring SaaS revenue, and fast-moving privacy rules � details that sprawl across hundreds of pages. If you’ve ever searched “What does IAS report in its 10-K?� you know the challenge. Stock Titan’s AI-powered analysis turns those dense disclosures into plain language so you can move from confusion to clarity in minutes.
Whether you need the IAS annual report 10-K simplified, a quick look at an IAS quarterly earnings report 10-Q filing, or Integral Ad Science 8-K material events explained, our platform delivers every document the moment it hits EDGAR. Instantly surface Integral Ad Science insider trading Form 4 transactions, monitor Integral Ad Science Form 4 insider transactions real-time, and compare revenue shifts across regions without downloading a single PDF. Natural-language summaries answer searches like “How does IAS recognize revenue?� or “Which customers represent more than 10 % of sales?�
Because ad-tech valuations hinge on growth metrics and data costs, investors routinely dig into sections dealing with platform concentration, research spend, and data-privacy risk. Our AI highlights those passages, links them to ratio analysis, and pairs them with Integral Ad Science earnings report filing analysis so you can act quickly. You’ll also find IAS proxy statement executive compensation details, understanding IAS SEC documents with AI context, and Integral Ad Science executive stock transactions Form 4 alerts � all organized in one place. Complex filings, clear answers.
Integral Ad Science Holding Corp. (IAS) � Form 4 insider transaction: CEO and Director Lisa Utzschneider reported a sale of 8,285 common shares on 07/10/2025 at a weighted-average price of $8.29 per share. The filing states the sale was a mandatory disposition to cover tax liabilities arising from the settlement of market stock units. Following the transaction, Utzschneider remains the beneficial owner of 371,031 IAS shares, all held directly. No derivative security transactions were reported.
The sale represents a minor reduction in her overall ownership and appears routine rather than indicative of a change in strategic sentiment. No other executives or insiders were listed in this filing, and there is no accompanying earnings data or operational update.
Disc Medicine, Inc. (NASDAQ: IRON) � Form 144 filing overview
An insider—identified in the filing’s prior-sales table as Jean Franchi—has notified the SEC of an intention to sell 2,000 common shares of Disc Medicine. The shares will be routed through Morgan Stanley Smith Barney LLC on or about 10 July 2025. Based on the filing’s quoted price, the aggregate market value of the proposed sale is $111,720. The company has 34,634,000 shares outstanding; the proposed disposition therefore represents roughly 0.006 % of shares outstanding.
Acquisition background: The shares derive from restricted stock units (RSUs) granted on 15 Feb 2025. No cash payment was required when the RSUs were awarded.
Recent trading history: The same account executed a Rule 10b5-1 sale of 2,000 shares on 16 Jun 2025 for $104,518.80 in gross proceeds.
Key take-aways for investors:
- The filing is a routine Form 144 notice; it does not itself execute a sale but provides advance disclosure.
- The dollar amount is modest relative to Disc Medicine’s market capitalization and float, indicating limited direct market impact.
- Successive 2,000-share sales within a month may nevertheless be monitored as an insider-selling trend, especially if additional filings appear.
UBS AG is offering $1.825 million of Trigger Autocallable Contingent Yield Notes linked to the common stock of Amgen Inc. (AMGN). The three-year notes are unsubordinated, unsecured debt obligations of UBS AG (London branch) and settle on 14 July 2025, with final maturity on 14 July 2028, unless automatically called earlier.
Key commercial terms
- Issue price: $10.00 per note (minimum purchase 100 notes).
- Estimated initial value: $9.65 per note (reflects underwriting discount, hedging & funding costs).
- Underlying: Amgen common stock � initial level $300.37.
- Contingent coupon: 8.00% p.a. ($0.20 quarterly) paid only if AMGN closes � coupon barrier on a given observation date.
- Coupon barrier & downside threshold: $186.23 (62% of initial level).
- Automatic call: Quarterly, first possible on 14 Jan 2026; triggered if AMGN closes � initial level on any observation date. Holder then receives principal plus latest coupon and the note terminates.
- Principal repayment: � 100% at maturity if not previously called and AMGN � downside threshold. � Otherwise, cash redemption = $10 × (1 + underlying return), exposing investor to full downside below the threshold, up to 100% loss.
Risk highlights
- No guaranteed coupons; investors may receive few or none.
- Market risk mirrors downside of AMGN once the 38% buffer is pierced.
- Credit risk of UBS AG; notes are not FDIC-insured.
- Limited liquidity: unlisted, secondary market making at UBS discretion only.
- Conflict-of-interest and pricing considerations: issue price exceeds model value; early secondary quotes may temporarily include a premium that amortises within three months.
Timeline
- Trade date: 10 Jul 2025
- Settlement: 14 Jul 2025 (T+2)
- 12 scheduled quarterly observation dates; final valuation 12 Jul 2028
Illustrative outcomes
- Best case: first call (�6 months) delivers $10.20 total, a 4.0% absolute return in half a year.
- Hold to maturity with AMGN � threshold: receive principal plus any final coupon (maximum compounded return �8% p.a. if all coupons are paid and never called).
- AMGN at 41% below initial at maturity (example): redemption $5.89, plus $0.20 prior coupon = 39% loss.
The structure suits investors comfortable with single-stock exposure, contingent income and potential early redemption, who can withstand significant capital loss and the credit risk of UBS.
On 7 July 2025, Integral Ad Science Holding Corp. (IAS) Chief Accounting Officer Alexis Gil II filed a Form 4 reporting the sale of 1,962 shares of IAS common stock at a weighted-average price of $8.43. The transaction was identified as a mandatory sale to cover tax obligations triggered by the vesting of restricted stock units. Following the sale, the executive’s direct ownership stands at 173,825 shares. No derivative positions or additional transactions were disclosed, and the filing does not reference a Rule 10b5-1 trading plan. Given the limited size of the sale (�1.1 % of the insider’s holdings) and its tax-related nature, the event is considered routine with minimal impact on the company’s insider-ownership profile.
Integral Ad Science Holding Corp. (IAS) filed a Form 4 disclosing that Chief Executive Officer and Director Lisa Utzschneider acquired 15,767 shares of IAS common stock on 07/03/2025. The shares were received at $0 cost through the automatic vesting (transaction code M) of previously granted Market Stock Units (MSUs) dated 04/03/2023. No shares were sold in connection with the vesting event.
Following the transaction, Utzschneider’s direct ownership rises to 394,220 common shares, while she continues to hold 413,892 MSUs that remain subject to future vesting. The MSU award represents up to 225% of target shares depending on share-price performance, vests 25% on 04/03/2024, and thereafter in equal quarterly installments over three years.
The filing indicates ongoing equity alignment between the CEO and shareholders but is a scheduled incentive-plan vesting rather than an open-market purchase, so its market impact is typically modest.
Shimmick Corporation (SHIM) � Form 144 filing. Affiliate Mitchell B. Goldsteen has notified the SEC of his intent to sell 7,000 common shares through TD Securities on or about 08 July 2025 at an aggregate market value of $13,812.40. The proposed sale represents only 0.02 % of the company’s 34.7 million shares outstanding. However, the filing also discloses that Goldsteen has already disposed of approximately 198,160 shares over the last three months, generating roughly $340k in gross proceeds. While the magnitude of each sale is immaterial to the float, the steady pattern of insider sales may draw attention from investors monitoring sentiment among key holders. No new operational or financial information is provided in the notice; the filer affirms he possesses no undisclosed material information.
Integral Ad Science Holding Corp. (IAS) filed a Form 144 indicating that an insider intends to sell up to 1,962 common shares on or about 07 July 2025 through Fidelity Brokerage Services on NASDAQ. The shares, valued at approximately $16,539.47, were recently acquired via restricted-stock vesting on 01 July 2025 as compensation. A prior sale of 2,851 shares for $22,707.36 was executed on 03 June 2025 by the same insider, Alexis Gil II. The planned sale represents about 0.0012% of IAS’s 165 million shares outstanding, signalling limited dilution or ownership impact. The filing fulfills SEC Rule 144 disclosure requirements, allowing public investors to track insider trading activity and gauge sentiment.
ProKidney Corp. (PROK) filed a Post-Effective Amendment No. 1 to its previously effective Form S-4 on 3 July 2025 to reflect the company’s completed domestication from the Cayman Islands to Delaware, which became effective 1 July 2025. The amendment, submitted under Rule 414(d), formally adopts the earlier Cayman Islands registration statement as the successor Delaware issuer’s own, avoiding any lapse in Securities Act or Exchange Act coverage.
Key points for investors:
- Corporate domicile change: The legal entity is now a Delaware corporation governed by the DGCL, its new certificate of incorporation and by-laws. Delaware’s well-established case law may enhance predictability around shareholder rights and M&A activity.
- Capital continuity: Every Class A and Class B ordinary share of the Cayman entity automatically converted 1-for-1 into the same class of Delaware common stock with identical proportional equity interests; no dilution or change in share count occurred.
- Listing & identifiers: Shares continue trading on Nasdaq Capital Market under ticker “P¸é°¿°â€�; however, the CUSIP changed to 74291D 104.
- Management & operations unchanged: Business, assets, liabilities, fiscal year and the full board/executive team remain exactly the same post-domestication.
- Expert consents & exhibits: New opinions from Akin Gump (Ex. 5.1) and EY’s audit consent (Ex. 23.1) are filed; Delaware charter and by-laws are incorporated by reference.
- Indemnification framework: The filing details DGCL provisions and the company’s charter/by-law clauses that limit director & officer liability and permit broad indemnification, supplemented by D&O insurance and individual indemnification agreements.
No new securities are being offered and the amendment is largely administrative; it ensures continuous SEC registration and updates the governing law and disclosure cross-references to reflect the Delaware entity.
América Móvil, S.A.B. de C.V. (AMX) is conducting a peso-denominated reopening of three outstanding series of senior notes, adding Ps.15.5 billion to its long-dated local-currency curve.
- Size & structure: Ps.6.0 bn 10.125% notes due 2029, Ps.6.0 bn 9.500% notes due 2031 and Ps.3.5 bn 10.300% notes due 2034. All tranches are fungible with, and will form single series alongside, prior issuances, taking the aggregate size of each series to Ps.23.5 bn (2029 & 2034) and Ps.23.0 bn (2031).
- Pricing: Issuance prices of 102.778%, 100.372% and 102.856% translate into yields of c.9.63%, 9.44% and 9.91% respectively. Underwriting spreads are minimal (0.125%�0.231%), signalling healthy demand.
- Proceeds & use: Gross proceeds before expenses amount to Ps.15.76 bn (≈US$775.8 m). Management will apply funds to general corporate purposes and short-term debt repayment; an amount equal to the net proceeds of the 2031 and 2034 tranches will be earmarked for Eligible Projects under the company’s Sustainable Finance Framework (renewable energy, energy efficiency, digital inclusion, etc.).
- Terms: Unsecured, unsubordinated obligations ranking pari-passu with other senior debt; effectively subordinated to secured obligations and subsidiary liabilities. Optional redemption is at make-whole prior to par-call dates (Dec-22-28, Oct-27-30 & Oct-30-33) and at par thereafter. A tax gross-up applies unless withholding stays �4.9%.
- Capitalisation impact: As at 31 Mar 25, total consolidated debt stood at Ps.588 bn (US$29 bn) and would rise to Ps.614 bn post-issuance before netting cash deployment. Parent-level unsecured debt is Ps.404 bn; subsidiary debt Ps.184 bn. Pro-forma long-term debt/total capital inches up from 51.1% to 52.5% prior to application of proceeds.
- Risk highlights: high coupons enlarge interest burden; notes lack subsidiary guarantees (notably from Telcel); ESG-label risk if projects fail to align with evolving standards; upcoming IFRS-S sustainability disclosure rules could raise compliance costs.
Overall, the deal lengthens AMX’s local-currency maturity ladder, secures funds for liability management and supports its sustainability agenda, but marginally elevates leverage and interest expense.
Integral Ad Science Holding Corp (IAS) has filed a Form 3 (Initial Statement of Beneficial Ownership) announcing the appointment of Alpana Wegner as Chief Financial Officer. The filing, dated June 28, 2025, discloses Wegner's initial beneficial ownership position upon assuming the role.
Key details from the filing:
- Event Date: June 10, 2025
- Filing Type: Individual filing (not joint)
- Current Holdings: No securities beneficially owned at time of filing
- Business Address: 12 E. 49th Street, 20th Floor, New York, NY 10017
The Form 3 filing was executed by Yossi Almani through Power of Attorney on June 18, 2025. This mandatory filing complies with Section 16(a) of the Securities Exchange Act of 1934, requiring directors, officers, and 10% shareholders to disclose their securities ownership and trading activities.